10-Q: Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Elicio Therapeutics, a clinical-stage biotechnology company, announced its second quarter 2024 financial results, highlighting ongoing clinical development and financial challenges.

Summary

• Elicio Therapeutics reported a net loss of $7.2 million for the three months ended June 30, 2024, and a net loss of $19.1 million for the six months ended June 30, 2024.
• The company's research and development expenses increased to $8.2 million for the three months ended June 30, 2024, and $15.7 million for the six months ended June 30, 2024, primarily due to clinical trial expenses.
• General and administrative expenses were $2.7 million for the three months ended June 30, 2024, and $5.4 million for the six months ended June 30, 2024.
• As of June 30, 2024, Elicio had $3.4 million in cash and cash equivalents and an accumulated deficit of $161.3 million.
• The company has raised $152 million since inception through various means including equity offerings, debt financing and the merger with Angion Biomedica Corp.
• Elicio is facing substantial doubt about its ability to continue as a going concern due to its cash position and cash runway.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including substantial losses, limited cash, and a going concern warning, which overshadows the positive aspects of clinical development and recent capital raises. The material weaknesses in internal controls also contribute to a negative sentiment.

Positives

• The company completed a public offering on July 1, 2024, raising approximately $10.9 million in net proceeds.
• Elicio secured a convertible note financing in August 2024, raising approximately $19.7 million in net proceeds.
• The company is actively advancing its lead product candidate, ELI-002, to late-stage clinical trials.
• Elicio is expanding its pipeline of product candidates and seeking regulatory approval for its investigational medicines.

Negatives

• Elicio has incurred significant operating losses since inception, with a net loss of $19.1 million for the first six months of 2024.
• The company has an accumulated deficit of $161.3 million as of June 30, 2024.
• Elicio's cash and cash equivalents were $3.4 million as of June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to its current cash position and cash runway.
• The company's internal controls over financial reporting have material weaknesses.

Risks

• Elicio faces substantial doubt about its ability to continue as a going concern due to its current cash position and cash runway.
• The company's internal controls over financial reporting have material weaknesses, which could lead to misstatements in financial reporting.
• The company is dependent on raising additional capital to fund its operations and product development.
• There is no assurance that financing will be available when needed or on favorable terms.
• The company's largest stockholder has significant influence over the company, which could limit other stockholders' ability to influence key transactions.
• The terms of the convertible note arrangement with GKCC, an entity controlled by a member of the board, places certain restrictions on the company's operating and financial flexibility.
• The company is subject to risks associated with clinical trials, regulatory approvals, and market acceptance of its product candidates.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The company's cash on hand is expected to fund operations into the second quarter of calendar year 2025.

Management Comments

• Management believes that the company's AMP technology can generate a robust T cell response that can potentially provide meaningful clinical benefit.
• Management plans to address the going concern issue through the sale of common stock or other securities, debt financings, or through other capital sources.

Industry Context

Elicio is operating in the competitive biotechnology sector, focusing on immunotherapies for cancer and infectious diseases. The company's approach of targeting lymph nodes with its AMP technology is aimed at improving the efficacy of cancer vaccines, which is a key area of focus in the industry.

Comparison to Industry Standards

• Elicio's financial position, with a significant accumulated deficit and limited cash reserves, is not uncommon for clinical-stage biotechnology companies.
• The company's focus on developing immunotherapies aligns with current industry trends, but the success of its approach is dependent on clinical trial outcomes.
• The company's reliance on external funding is typical for companies in this sector, but the going concern risk highlights the challenges of securing sufficient capital.
• The company's research and development expenses are in line with other companies in the sector, but the company's ability to generate revenue is dependent on the success of its clinical trials.

Related Party Transactions

• The company paid $0 for both the three and six months ended June 30, 2024, for consulting services provided by an entity affiliated with the company's former interim chief financial officer and former board member.
• In March 2024, the company entered into a subscription agreement with an entity controlled by a director of the company for the issuance of pre-funded warrants.
• Following the Public Offering described in Note 16 Subsequent Events below, Yekaterina Chudnovsky, a member of the Companys board of directors, and Jay Venkatesan, a member of the Companys board of directors, and trusts affiliated with Jay Venkatesan, purchased 1,600,000 July Pre-Funded Warrants and July Common Warrants and 200,000 July Pre-Funded Warrants and July Common Warrants, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be concerned about job security due to the company's financial challenges.
• Customers and partners may be concerned about the company's ability to continue its operations and product development.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company will continue to advance its lead product candidate, ELI-002, to late-stage clinical trials.
• The company will continue to expand its pipeline of product candidates.
• The company will seek regulatory approval for its investigational medicines.
• The company will continue to monitor and upgrade its internal controls as necessary or appropriate for its business.

Key Dates

Keywords

biotechnology, immunotherapy, clinical trials, cancer vaccine, ELI-002, financial results, going concern, capital raise, research and development, lymph node targeting